Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus
Authors
Keywords
-
Journal
ARTHRITIS CARE & RESEARCH
Volume 69, Issue 1, Pages 115-123
Publisher
Wiley
Online
2016-07-07
DOI
10.1002/acr.22971
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
- (2016) I N Bruce et al. LUPUS
- Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
- (2015) Margherita Zen et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
- (2015) J. S. Hui-Yuen et al. JOURNAL OF RHEUMATOLOGY
- Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight
- (2015) A Doria et al. LUPUS
- Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis
- (2015) Francesca Pierotti et al. PLoS One
- Real life experience on the effect of Belimumab in patients with active systemic lupus
- (2015) Morton Scheinberg et al. SpringerPlus
- OP0048 Outcomes in Systemic Lupus Erythematous (SLE) Patients Treated with Belimumab in Clinical Practice Settings: Results from the Observe Study in Germany
- (2014) A. Schwarting et al. ANNALS OF THE RHEUMATIC DISEASES
- Patterns of systemic lupus erythematosus expression in Europe
- (2014) R. Cervera et al. AUTOIMMUNITY REVIEWS
- Optimizing outcome in SLE: treating-to-target and definition of treatment goals
- (2014) Andrea Doria et al. AUTOIMMUNITY REVIEWS
- In-/off-label use of biologic therapy in systemic lupus erythematosus
- (2014) Mariele Gatto et al. BMC Medicine
- Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: A new anti-BLyS human monoclonal antibody
- (2014) Husein Husein-ElAhmed et al. Indian Journal of Dermatology Venereology & Leprology
- Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment
- (2014) M Jüptner et al. LUPUS
- Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus—A case report
- (2014) Abhijeet Danve et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Evaluation of Use of Belimumab In Clinical Practice Settings (Observe Study) In Spain: Health Resource Utilization and Labour Absenteeism
- (2014) J. Cortés et al. VALUE IN HEALTH
- Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
- (2014) Maria Lucia Specchia et al. Biomed Research International
- Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman
- (2013) EE Fließer et al. LUPUS
- Premature coronary heart disease in SLE: can we prevent progression?
- (2013) L Iaccarino et al. LUPUS
- Annual direct medical cost of active systemic lupus erythematosus in five European countries
- (2012) Andrea Doria et al. ANNALS OF THE RHEUMATIC DISEASES
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
- (2012) Susan Manzi et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term complications of past glucocorticoid use
- (2012) Luciana P.C. Seguro et al. AUTOIMMUNITY REVIEWS
- Emerging and critical issues in the pathogenesis of lupus
- (2012) Mariele Gatto et al. AUTOIMMUNITY REVIEWS
- Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
- (2012) DJ Wallace et al. LUPUS
- Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
- (2012) MA Dooley et al. LUPUS
- Global trends, potential mechanisms and early detection of organ damage in SLE
- (2012) Anselm Mak et al. Nature Reviews Rheumatology
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort
- (2011) R. Lopez et al. RHEUMATOLOGY
- Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome
- (2010) A. J. STEIMAN et al. JOURNAL OF RHEUMATOLOGY
- Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus
- (2010) J. Nossent et al. LUPUS
- Cutaneous Lupus Erythematosus
- (2009) Hobart W. Walling et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Prednisone, Lupus Activity, and Permanent Organ Damage
- (2009) M. THAMER et al. JOURNAL OF RHEUMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now